Page last updated: 2024-09-04

cox 189 and Cardiovascular Diseases

cox 189 has been researched along with Cardiovascular Diseases in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (83.33)	29.6817
2010's	2 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Capra, V; Dahlén, SE; Folco, G; Rovati, GE; Sala, A	1
Macdonald, TM; Mackenzie, IS; Wei, L	1
Doggrell, SA	1
Ehrsam, E; Garaud, JJ; Gitton, X; Hoexter, G; Krammer, G; Matchaba, P; Mellein, B; Olson, M; Orloff, J; Sloan, VS	1
Goldstein, JL; Rosenberg, JA	1
Marwali, MR; Mehta, JL	1
Deray, G; Montalescot, G; Sibilia, J	1
Deray, G; Héloire, F; Valat, JP	1
Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW	1
Bannwarth, B; Bérenbaum, F	1
Baraf, HS	1
Fleischmann, R; Notter, M; Patel, NP; Reginster, JY; Sallstig, P; Tannenbaum, H	1

Reviews

8 review(s) available for cox 189 and Cardiovascular Diseases

Article	Year
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis. European journal of clinical pharmacology, 2013, Volume: 69, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Male; Middle Aged; Osteoarthritis	2013
The safety of lumiracoxib when used in the treatment of arthritis. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:2 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Organic Chemicals; Stomach Ulcer	2005
Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clinical therapeutics, 2005, Volume: 27, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Databases, Factual; Diclofenac; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Randomized Controlled Trials as Topic	2005
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. Thrombosis and haemostasis, 2006, Volume: 96, Issue:4 Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2	2006
[What do we know about the cardiovascular toxicity of the NSAIDs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
Lumiracoxib in the management of osteoarthritis and acute pain. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:10 Topics: Acute Disease; Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Approval; Humans; Osteoarthritis; Pain; Peptic Ulcer; Risk Assessment; Treatment Outcome	2007
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Current pharmaceutical design, 2007, Volume: 13, Issue:22 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones	2007

Trials

4 trial(s) available for cox 189 and Cardiovascular Diseases

Article	Year
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis. European journal of clinical pharmacology, 2013, Volume: 69, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Male; Middle Aged; Osteoarthritis	2013
Safety and efficacy of lumiracoxib compared with NSAIDs. Nature clinical practice. Gastroenterology & hepatology, 2005, Volume: 2, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Diseases; Humans; Incidence; Organic Chemicals; Osteoarthritis; Risk Factors; Time Factors; Treatment Outcome	2005
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Annals of the rheumatic diseases, 2007, Volume: 66, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Heart Defects, Congenital; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis	2007
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC musculoskeletal disorders, 2008, Mar-07, Volume: 9 Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Europe; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome; United States	2008

Other Studies

1 other study(ies) available for cox 189 and Cardiovascular Diseases

Article	Year
Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends in pharmacological sciences, 2010, Volume: 31, Issue:3 Topics: Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Endothelium, Vascular; Humans; Receptors, Thromboxane A2, Prostaglandin H2	2010